nach oben

Erschienen in:

01.12.2011 | Original Article

New considerations on the management of osteoporosis in Central and Eastern Europe (CEE): summary of the “3rd Summit on Osteoporosis—CEE”, November 2009, Budapest, Hungary

verfasst von: Péter Lakatos, Ádám Balogh, Edward Czerwinski, Hans P. Dimai, Didier Hans, Gerold Holzer, Roman S. Lorenc, Vladimir Palicka, Barbara Obermayer-Pietsch, Jan Stepan, István Takács, Heinrich Resch, on behalf of the Members of the “3rd Summit on Osteoporosis—Central and Eastern Europe (CEE)”

Erschienen in: Archives of Osteoporosis | Ausgabe 1-2/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

In November 2009, the “3rd Summit on Osteoporosis—Central and Eastern Europe (CEE)” was held in Budapest, Hungary. The conference aimed to tackle issues regarding osteoporosis management in CEE identified during the second CEE summit in 2008 and to agree on approaches that allow most efficient and cost-effective diagnosis and therapy of osteoporosis in CEE countries in the future.

Discussion

The following topics were covered: past year experience from FRAX® implementation into local diagnostic algorithms; causes of secondary osteoporosis as a FRAX® risk factor; bone turnover markers to estimate bone loss, fracture risk, or monitor therapies; role of quantitative ultrasound in osteoporosis management; compliance and economical aspects of osteoporosis; and osteoporosis and genetics. Consensus and recommendations developed on these topics are summarised in the present progress report.

Conclusion

Lectures on up-to-date data of topical interest, the distinct regional provenances of the participants, a special focus on practical aspects, intense mutual exchange of individual experiences, strong interest in cross-border cooperations, as well as the readiness to learn from each other considerably contributed to the establishment of these recommendations. The “4th Summit on Osteoporosis—CEE” held in Prague, Czech Republic, in December 2010 will reveal whether these recommendations prove of value when implemented in the clinical routine or whether further improvements are still required.

O’Neil TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010–1018CrossRef

Strom O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79:269–280PubMedCrossRef

Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20–26PubMedCrossRef

Lorenc RS, Resch H (2009) Management of osteoporosis in Central and Eastern Europe (CEE): conclusions of the “2nd Summit on Osteoporosis—CEE”, 21–22 November 2008, Warsaw, Poland. Arch Osteoporos 4:1–8PubMedCrossRef

Franek E, Karczmarewicz E, Misiorowski W et al (2009) Treatment benefits evaluation in osteoporosis—position of the Summit International Conference on Osteoporosis—Central Eastern Europe held 21–22 November 2008, Warsaw, Poland. Bone 44:S374–S375CrossRef

Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMedCrossRef

McCloskey EV, Johansson H, Oden A, Kanis JA (2009) From relative risk to absolute fracture risk calculation: the FRAX® algorithm. Curr Osteoporos Rep 7:77–83PubMedCrossRef

Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX® in osteoporosis. Osteoporos Int 21((Suppl 2)):S407–S413PubMedCrossRef

Pluskiewicz W, Adamczyk P, Franek E, Leszczynski P, Sewerynek E, Wichrowska H, Napiorkowska L, Kostyk T, Stuss M, Stepien-Klos W, Golba KS, Drozdzowska B (2010) Ten-year probability of osteoporotic fracture in 2012 Polish women assessed by FRAX® and nomogram by Nguyen et al.—conformity between methods and their clinical utility. Bone 46:1661–1667PubMedCrossRef

10.

Tałałaj M (2009) Bone fracture risk at secondary osteoporoses. Third Central European Congress on Osteoporosis and Osteoarthritis, Krakow, Poland. Abstract L33

11.

Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323PubMedCrossRef

12.

Genant HK, Delmas PD, Chen P, Jiang Y, Eriksen EF, Dalsky GP, Marcus R, San Martin J (2007) Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 18:69–76PubMedCrossRef

13.

Chen P, Krege JH, Adachi JD, Prior JC, Tenenhouse A, Brown JP, Papadimitropoulos E, Kreiger N, Olszynski WP, Josse RG, Goltzman D (2009) Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res 24:495–502PubMedCrossRef

14.

Bone Health and Osteoporosis: a report of the surgeon general 2004. U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Rockville, MD, US; http://www.surgeongeneral.gov/library/bonehealth/Executive_Summary.html#Chapter8AssessingtheRiskofBoneDiseaseandFracture, accessed 2 July 2010

15.

Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162PubMedCrossRef

16.

van Staa TP, Leufkens HG, Cooper C (1991) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRef

17.

Meenan RF, Kazis LE, Anthony JM, Wallin BA (1991) The clinical and health status of patients with recent-onset rheumatoid arthritis. Arthritis Rheum 34:761–765PubMedCrossRef

18.

Kanis JA, Burlet N, Cooper C, Delmas PD, ReginsterJ-Y BF, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRef

19.

Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762–2767PubMedCrossRef

20.

Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970PubMedCrossRef

21.

Stepan JJ, Zikán V (2003) Calcitonin load test to assess the efficacy of salmon calcitonin. Clin Chim Acta 336:49–55PubMedCrossRef

22.

Holzer G, Noske H, Lang T, Holzer L, Willinger U (2005) Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 146:13–17PubMedCrossRef

23.

Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F (2005) BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int 16:943–952PubMedCrossRef

24.

Hellman J, Käkönen SM, Matikainen MT, Karp M, Lövgren T, Väänänen HK, Pettersson K (1996) Epitope mapping of nine monoclonal antibodies against osteocalcin: combinations into two-site assays affect both assay specificity and sample stability. J Bone Miner Res 11:1165–1175PubMedCrossRef

25.

Seibel MJ, Lang M, Geilenkeuser WJ (2001) Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 47:1443–1450PubMed

26.

Faulkner KG, von Stetten E, Miller P (1999) Discordance in patient classification using T-scores. J Clin Densitom 2:343–350PubMedCrossRef

27.

Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15PubMedCrossRef

28.

Kanis J (2009) International Osteoporosis Foundation, 8th European Union osteoporosis consultation panel meeting, Brussels, Belgium. http://www.iofbonehealth.org/download/osteofound/filemanager/policy_advocacy/EU-consultation-panel-meetings/8th-EU-consultation-panel-meeting071009.pdf, accessed 2 July 2010

29.

Report of the International Osteoporosis Foundation 2008: osteoporosis in the European Union in 2008: 10 years of progress and ongoing challenges. http://www.sante.public.lu/publications/maladies-traitements/osteoporose/osteoporosis-eu-2008/osteoporosis-eu-2008.pdf, accessed 2 July 2010

30.

Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460PubMedCrossRef

31.

Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jönsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 18:711–719PubMedCrossRef

32.

Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRef

33.

Ström O, Borgström F, Kanis JA, Jönsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23–34PubMedCrossRef

34.

Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916PubMedCrossRef

35.

Rivadeneira F, Styrkársdottir U, Estrada K et al (2009) Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 41:1199–1206PubMedCrossRef

36.

Little RD, Carulli JP, Del Mastro RG et al (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11–19PubMedCrossRef

37.

Gong Y, Slee RB, Fukai N et al (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513–523PubMedCrossRef

38.

Levasseur R, Lacombe D, de Vernejoul MC (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72:207–214PubMedCrossRef

39.

van Meurs JB, Trikalinos TA, Ralston SH et al (2008) Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA 299:1277–1290PubMedCrossRef

Titel: New considerations on the management of osteoporosis in Central and Eastern Europe (CEE): summary of the “3rd Summit on Osteoporosis—CEE”, November 2009, Budapest, Hungary
verfasst von: Péter Lakatos
Ádám Balogh
Edward Czerwinski
Hans P. Dimai
Didier Hans
Gerold Holzer
Roman S. Lorenc
Vladimir Palicka
Barbara Obermayer-Pietsch
Jan Stepan
István Takács
Heinrich Resch
on behalf of the Members of the “3rd Summit on Osteoporosis—Central and Eastern Europe (CEE)”
Publikationsdatum: 01.12.2011
Verlag: Springer-Verlag
Erschienen in: Archives of Osteoporosis / Ausgabe 1-2/2011
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-010-0048-2

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

25.04.2024 | Hypertonie | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

New considerations on the management of osteoporosis in Central and Eastern Europe (CEE): summary of the “3rd Summit on Osteoporosis—CEE”, November 2009, Budapest, Hungary

Abstract

Introduction

Discussion

Conclusion

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Introduction

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-2/2011

Older age and lower adiposity predict better 25-hydroxy vitamin D concentration in Inuit adults: International Polar Year Inuit Health Survey, 2007–2008

Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model

Femoral neck bone mineral density and 10-year absolute fracture risk in a national representative sample of Bulgarian women aged 50 years and older

Serum 25-hydroxyvitamin D, bone mineral density, and non-vertebral fracture risk in community-dwelling older men: results from Mr. Os, Hong Kong

Normative calcaneal quantitative ultrasound data for the indigenous Shuar and non-Shuar Colonos of the Ecuadorian Amazon

Influence of menopause on mandibular bone quantity and quality in Japanese women receiving dental implants

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie